Effect of IL-18 binding protein on hepatic ischemiareperfusion injury induced by infrarenal aortic occlusion

Mustafa Ozsoy,Yucel Gonul,Ahmet Bal,Ziya Taner Ozkececi,Ruchan Bahadir Celep,Fahri Adali,Omer Hazman,Ahmet Kocak,Murat Tosun 대한외과학회 2015 Annals of Surgical Treatment and Research(ASRT) Vol.88 No.2

Purpose: Severe local and systemic tissue damage called ischemia/reperfusion (IR) injury occurs during the period of reperfusion. Free oxygen radicals and proinflammatory cytokines are responsible for reperfusion injury. IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting. The present study aimed to investigate whether IL-18BP had a protective role in remote organ hepatic IR injury. Methods: Wistar-Albino rats were divided into three groups that contained seven rats. Group I (sham): Laparotomy and infrarenal abdominal aorta (AA) dissection were done but no clamping was done. Group II (I/R): The infrarenal AA was clamped by atraumatic microvascular clamp for 30 minutes and then was exposed to 90 minutes of reperfusion. Group III (IR + IL-18BP): 75 μg/kg of IL-18BP in 0.9% saline (1 mL) was administered 30 minutes before infrarenal AA dissection and clamping; 30 minutes of ischemia was applied and then was exposed to 90 minutes of reperfusion. Results: Serum AST, ALT, and LDH levels were remarkably higher in IR group and returned to normal levels in treatment group. The proinflammatory cytokine levels had decreased in treatment group, and was statistically significant compared with the IR group. Serum levels of total oxidant status and oxidative stress index decreased and levels of total antioxidant status increased by IL-18BP. Conclusion: This study suggested that IL-18BP has antioxidant, anti-inflammatory and hepatoprotective effects in cases of IR with infrarenal AA induced liver oxidative damage.

Effect of demagnetization faults on line start AF‑PMSM performance

Mustafa Eker,Mustafa Ozsoy 전력전자학회 2022 JOURNAL OF POWER ELECTRONICS Vol.22 No.6

This study is concerned with irreversible demagnetization faults in axial fl ux permanent magnet synchronous motors (AFPMSM). Line start capability was provided to the AF-PMSM by making changes in its traditional rotor architecture. With this architecture, the motor operates as an asynchronous motor in the transient state and as a synchronous motor in the steady state. In this study, the impacts of an irreversible demagnetization fault on motor performance, which occurs in motors due to various reasons, is investigated. The four poles of the used AF-PMSM have 5.5 kW of shaft power. Each pole is comprised of fi ve identical magnets. Diff erent rates (20%, 40%, and 60%) of demagnetization failure were created in a single pole. The data acquired from the faulty motors were compared to data from a healthy motor. The results indicate that irreversible demagnetization faults have an adverse impact on motor performance. It was observed that the experimentally created demagnetization faults increase the current drawn by the motor. In addition, they cause a decrease in both the power factor and effi ciency. However, the faults did not have an adverse impact on the starting capability of the motor. The unique aspect of the present study is that it is the fi rst time the impacts of demagnetization faults on the performance of line start AF-PMSMs have been examined.

Serum Ghrelin and Leptin Levels in Patients with Depression and the Effects of Treatment

Saliha Ozsoy,Aslı Besirli,Ummuhan Abdulrezzak,Mustafa Basturk 대한신경정신의학회 2004 PSYCHIATRY INVESTIGATION Vol.1 No.2

Objective-Ghrelin and leptin, appetite-regulating hormones, play a role in mood regulation. Current data about the relation between leptin/ghrelin and depression are still controversial. This study aimed to investigate serum leptin and ghrelin levels in patients with depression and the effects of treatment on these levels. Methods-Serum ghrelin and leptin levels were measured before and after treatment with antidepressant drugs and/or electroconvulsive therapy in 28 patients with depression and once in 21 healthy controls. Results-Serum ghrelin levels of the patients were high in the pre-treatment. After the treatment, ghrelin levels were not different from those of the controls. We found no difference in serum levels of leptin between the patients and controls and no change with treatment. body mass index of the patients increased after the treatment especially in the drug-treated group. Conclusion-The present study found increased serum ghrelin levels in depressive patients and normalization with improving of depression but no alteration in leptin levels.

Serum Ghrelin and Leptin Levels in Patients with Depression and the Effects of Treatment

Saliha Ozsoy,Aslı Besirli,Ummuhan Abdulrezzak,Mustafa Basturk 대한신경정신의학회 2014 PSYCHIATRY INVESTIGATION Vol.11 No.2

Objective Ghrelin and leptin, appetite-regulating hormones, play a role in mood regulation. Current data about the relation between leptin/ghrelin and depression are still controversial. This study aimed to investigate serum leptin and ghrelin levels in patients with depression and the effects of treatment on these levels. Methods Serum ghrelin and leptin levels were measured before and after treatment with antidepressant drugs and/or electroconvulsive therapy in 28 patients with depression and once in 21 healthy controls. Results Serum ghrelin levels of the patients were high in the pre-treatment. After the treatment, ghrelin levels were not different from those of the controls. We found no difference in serum levels of leptin between the patients and controls and no change with treatment. body mass index of the patients increased after the treatment especially in the drug-treated group. Conclusion The present study found increased serum ghrelin levels in depressive patients and normalization with improving of depression but no alteration in leptin levels.

The Effects of Galantamine Hydrobromide Treatment on Dehydroepiandrosterone Sulfate and Cortisol Levels in Patients with Chronic Fatigue Syndrome

Tayfun Turan,Hasan Basri Izgi,Saliha Ozsoy,Fatih Tanrıverdi,Mustafa Basturk,Akif Asdemir,Aslı Beşirli,Ertugrul Esel,Seher Sofuoglu 대한신경정신의학회 2009 PSYCHIATRY INVESTIGATION Vol.6 No.3

Objective: Mental fatigue, cognitive disorders, and sleep disturbances seen in chronic fatigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypoactivity seen in CFS. Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4- week administration of galantamine hydrobromide, a selective cetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment. Methods: Basal levels of cortisol and DHEAS were measured in 29 untreated CFS patients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 20 healthy controls. In the patient group, four weeks after 8 ㎎/d galantamine hydrobromide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 patients who stayed in study were divided into two subgroups as responders and nonresponders according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) scores. Results: Important findings of this study are lower pre-and post-treatment cortisol levels and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, respectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which were normalized following four weeks’ treatment with 8 ㎎/d galantamine hydrobromide in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively). Conclusion: The findings of the decrease in basal DHEAS levels and DHEAS/cortisol molar ratios normalizing with galantamine treatment may give some support to the cholinergic deficit hypothesis in CFS. Objective: Mental fatigue, cognitive disorders, and sleep disturbances seen in chronic fatigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypoactivity seen in CFS. Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4- week administration of galantamine hydrobromide, a selective cetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment. Methods: Basal levels of cortisol and DHEAS were measured in 29 untreated CFS patients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 20 healthy controls. In the patient group, four weeks after 8 ㎎/d galantamine hydrobromide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 patients who stayed in study were divided into two subgroups as responders and nonresponders according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) scores. Results: Important findings of this study are lower pre-and post-treatment cortisol levels and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, respectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which were normalized following four weeks’ treatment with 8 ㎎/d galantamine hydrobromide in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively). Conclusion: The findings of the decrease in basal DHEAS levels and DHEAS/cortisol molar ratios normalizing with galantamine treatment may give some support to the cholinergic deficit hypothesis in CFS.